Regeneron loses key defense in 19 treatment patent lawsuit
By Blake Brittain
Oct 4 -Biotech company Regeneron Pharmaceuticals REGN.O lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment.
U.S. District Judge Philip Halpern rejected Regeneron's pretrial argument that he should throw out Allele Biotechnology and Pharmaceuticals' patent lawsuit over the treatment based on a federal law allowing the use of patented inventions to test drugs during the U.S. Food and Drug Administration application process.
Attorneys and spokespeople for Regeneron did not immediately respond to a request for comment on the decision. An attorney for Allele declined to comment.
The companies stipulated last year that Regeneron was liable for patent infringement if its "safe harbor" defense failed, leaving the amount of damages Regeneron owes to be determined at a future trial.
San Diego-based Allele sued Regeneron in 2021, accusing the rival biotech company of using Allele's fluorescent protein mNeonGreen to test its coronavirus antibody cocktail REGEN-COV without a license. Tarrytown, N.Y.-based Regeneron earned nearly $6.2 billion from sales of REGEN-COV that year, according to a company report.
Allele settled a lawsuit against Pfizer and BioNTech in 2022 over their use of the same protein in developing their COVID-19 vaccine Comirnaty.
Halpern denied Regeneron's earlier bid to dismiss the case in 2022 and said he needed more information before ruling on the company's safe harbor defense. The judge said on Friday that Regeneron was not immune from Allele's allegations, finding that mNeonGreen was "a research tool that is not under the scope of the safe harbor provision."
The case is Allele Biotechnology and Pharmaceuticals Inc v. Regeneron Pharmaceuticals Inc, U.S. District Court for the Southern District of New York, No. 7:20-cv-08255.
For Allele: David Anstaett, Martin Gilmore, Christopher Hanewicz, Andrew Dufresne, Elise Edlin and Maria Stubbings of Perkins Coie
For Regeneron: Michael Morin, David Frazier, Arlene Chow and Michelle Ernst of Latham & Watkins
Read more:
Regeneron, Pfizer sued for patent infringement over COVID antibody cocktail, vaccine
Pfizer, biotech firm end patent fight over COVID-19 vaccine
Regeneron must face patent lawsuit over COVID-19 treatment
Reporting by Blake Brittain in Washington
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
